Navigation Links
Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
Date:9/22/2008

Results and Preclinical Research at Upcoming Conferences

CALGARY, Sept. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced the participation of five of its collaborators and their schedule of presentations at four conferences through November 15, 2008 covering clinical trial results and preclinical research on REOLYSIN(R).

"It's an important time for Oncolytics as we begin to share additional results of our ongoing clinical trial and preclinical research programs for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is the results of these trials that should help us to determine the late-stage clinical path forward for REOLYSIN(R)."

Dr. Kevin Harrington and colleagues are scheduled to present a poster presentation entitled "Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting, being held in San Diego, California from October 31-November 2, 2008.

Prof. Hardev Pandha and colleagues are scheduled to present a poster presentation entitled "A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel to Patients with Advanced Malignancies" at the iSBTc annual meeting.

Dr. Monica Mita et al is scheduled to make two oral presentations, both entitled "A Phase II Study of Intravenous Reolysin (Wild Type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" at the Chemotherapy Foundation Symposium XXVI, being held in New York from November 4-8, 2008 and also at the Connective Tissue Oncology Society (CTOS) meeting, being held in London, U.K. from November 13-15, 2008.

Dr. Anders Kolb and colleagues are scheduled to deliver a poster presentation ent
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces that results of a large, ... melanoma patients with hepatic metastases with the Delcath ... in an on-line abstract at the American Society ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report deals with ... classical use mainly to describe the chromosome structure ... age of molecular biology, it is also referred ...
(Date:5/29/2015)... Results from a Phase III clinical ... ability to reduce the size of melanoma tumors in ... the Journal of Clinical Oncology. , The global, ... and IV melanoma, a potentially fatal form of skin ... evaluate the safety and efficacy of the oncolytic virus ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
... it has reached a definitive agreement with Microsoft (NASDAQ: ... of services will provide for the secure transferring of ... HealthVault accounts upon their request. Microsoft ... consumers gather, store and share health information online. ...
... 25, 2011  San Francisco-based healthcare IT company and ... of XMRI.com, a new B2C service that enables ... online. The system utilizes a ... national outsourced radiology service provider, USARAD.com. USARAD.com,s CEO, ...
... group at the University of Maryland (UMd), a multi-institution ... an age-old metallurgy technique to produce an alloy that ... sensors and micromechanical devices controlled by magnetism.* The alloy, ... other things, for not using rare-earth elements to achieve ...
Cached Biology Technology:Candelis and Microsoft Team Up to Empower Patients 2Candelis and Microsoft Team Up to Empower Patients 3Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of 'XMRI.com,' New System by USARAD.com 2Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of 'XMRI.com,' New System by USARAD.com 3New magnetic-field-sensitive alloy could find use in novel micromechanical devices 2
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... manufacturers in China . The order value ... of + 1 000 MSEK for 2015.   Jörgen ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... tried and failed to develop an HIV vaccine, primarily by ... to fend off the virus before it takes hold. So ... in people. Now, in research to be published March 15 ... have laid out a new approach. They have identified a ...
... What: The National Institute of Environmental Health Sciences (NIEHS), part ... a major presence at the annual Society of Toxicology ... and the National Toxicology Program (NTP), which NIEHS administers, ... the newest advances, applications and thinking in the field ...
... conservationists a fish-eye view of conditions, from overfishing to ... according to a new study. Until recently, scientists ... counts and catch estimates, said Charles Greene, Cornell professor ... published in the March issue (Vol. 22, No. 1) ...
Cached Biology News:A natural approach for HIV vaccine 2A natural approach for HIV vaccine 3Hear about emerging trends in toxicology research 2New tracking tags are providing fish-eye views of ways to manage depressed fisheries 2
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
... Steady gravity-fed delivery of buffer ... animal perfusion. Rat version. In Vivo ... results--Steady gravity-fed delivery of buffer and ... Easy to setup, use and clean--Complete ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
Biology Products: